Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06842498 is registered in ClinicalTrials.gov with Kyntra Bio as lead sponsor.

NCT NCT06842498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06842498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Kyntra Bio
Phase
Phase 2
Overall status
Recruiting
Start date
February 22, 2026
Completion date
March 31, 2028
Enrollment
75 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer